RxDoctor Payments Data

Matthew Lindquist, DO

Pediatrics · Prairie Village, KSNPI 1114360765

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,780 of the $84,287 with a category attached, or 85.2%. Lilly USA, LLC accounts for 65.5% of it on its own, with 7 other manufacturers making up the rest. Among pediatrics clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,287in general payments, 2019–2025

Across 180 payments — averaging $468.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$55K
  • Novo Nordisk$28K
  • Intuitive Surgical$222
  • AbbVie$215
  • Rhythm Pharmaceuticals, Inc.$120
  • Teva Pharmaceuticals USA, Inc.$87
  • plus $83 from 2 others

What the payments were for

  • Consulting fees$1,5302%
  • Speaking & faculty fees$71,78085%
  • Travel & lodging$6,9368%
  • Food & beverage$4,0325%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,287 in reported general payments places this provider in the 95th percentile of 314 pediatrics providers in Kansas.

See all pediatrics providers in Kansas

Medicare billing

Part B allowed, 2024
$1,047
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$79,551
MounjaroTirzepatide48$57,377
TrulicityDulaglutide23$34,507
JardianceEmpagliflozin20$22,188
FarxigaDapagliflozin Propanediol24$21,504
Naltrexone Hcl18$621
Metformin Hcl51$265
Bupropion XlBupropion Hcl15$231
Topiramate32$204
Carvedilol17$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$55,218$91,88471 claims
Novo NordiskOzempic$28,341$79,55150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 314 pediatrics providers in Kansas.

Other pediatrics in Prairie Village

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →